Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias
I Helmy,
JM Herre,
G Gee,
H Sharkey,
P Malone,
MJ Sauve,
JC Griffin,
and
MM Scheinman
Department of Medicine, University of California, San Francisco 94143-0214.
Efficacy, side effects and predictors of response for intravenous amiodarone were evaluated in 46 patients with recurrent drug-refractory sustained ventricular tachycardia or ventricular fibrillation, or both, who were treated with intravenous amiodarone. Of the 46 patients, 27 (58.5%) responded early to intravenous amiodarone and 6 (13%) showed a late response to amiodarone. The majority of patients who responded to intravenous amiodarone did so within the first 2 h of therapy, and all responded within 84 h. Patients with an ejection fraction greater than 25% were more likely to respond (p less than 0.05). Major side effects occurred in 13% of patients. The cumulative 2 year mortality rate due to arrhythmia recurrence or sudden death for responders discharged from the hospital was 23% and the cumulative overall 2 year mortality rate was 46%. In conclusion, intravenous amiodarone is rapidly effective in the majority of patients with recurrent ventricular tachycardia or ventricular fibrillation refractory to other drugs. The poor long-term outcome of patients who require this therapy, respond to it and are discharged on long-term oral amiodarone therapy warrants consideration of other long-term treatment of these patients. Use of intravenous amiodarone is an important new modality in the treatment of drug-refractory malignant ventricular arrhythmias.
This article has been cited by other articles:
|
|
|
|
 
P. Vassallo and R. G. Trohman
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
JAMA,
September 19, 2007;
298(11):
1312 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Part 4: Advanced Life Support
Circulation,
November 29, 2005;
112(22_suppl):
III-25 - III-54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Kowey, J. H. Levine, J. M. Herre, A. Pacifico, B. D. Lindsay, V. J. Plumb, D. L. Janosik, H. A. Kopelman, and M. M. Scheinman
Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients With Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation
Circulation,
December 1, 1995;
92(11):
3255 - 3263.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. M. Scheinman, J. H. Levine, D. S. Cannom, T. Friehling, H. A. Kopelman, D. A. Chilson, E. V. Platia, D. J. Wilber, and P. R. Kowey
Dose-Ranging Study of Intravenous Amiodarone in Patients With Life-Threatening Ventricular Tachyarrhythmias
Circulation,
December 1, 1995;
92(11):
3264 - 3272.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
X.-J. Du, M. D. Esler, and A. M. Dart
Sympatholytic Action of Intravenous Amiodarone in the Rat Heart
Circulation,
January 15, 1995;
91(2):
462 - 470.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P K Mazeika
Grand Rounds - Hammersmith Hospital: Complicated myocardial infarction Ventricular septal rupture is a surgical emergency
BMJ,
March 5, 1994;
308(6929):
643 - 645.
[Full Text]
|
|
|
|
|
|
|
INTRAVENOUS AMIODARONE EFFECTIVE AS EMERGENCY THERAPY
Journal Watch (General),
October 7, 1988;
1988(1007):
1 - 1.
[Full Text]
|
|
|
|
